Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDAH1 | O94760 | 3/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 6/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 5/20 | 0.42 |
| ▸ | NOS3 | P29474 | 4/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ARG2 | P78540 | 4/20 | 0.42 |
| ▸ | ARG1 | P05089 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2336576 | 1.00 | DDAH1 (0.47) | DDAH1SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL9903954 | 1.00 | DDAH1 (0.47) | DDAH1SLC1A2SLC1A1SLC1A3GRIK1 | |
| Cysteine SCHEMBL8080777 | 0.84 | PTGS1 (0.55) | DDAH1SLC1A2SLC1A1SLC1A3GRIK1 | |
| Methionine Sulfoxide SCHEMBL15538306 | 0.84 | SLC1A2 (0.50) | DDAH1SLC1A2SLC1A1SLC1A3GRIK1 | |
| Methionine Sulfoxide SCHEMBL15538307 | 0.84 | SLC1A2 (0.50) | DDAH1SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL1158176 | 0.84 | SLC1A2 (0.44) | DDAH1SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL18768255 | 0.84 | GSR (0.47) | SLC1A2SLC1A1SLC1A3GRIK1GRIK2 | |
| SCHEMBL17789224 | 0.84 | SLC1A2 (0.44) | DDAH1SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL7771850 | 0.83 | GSR (0.45) | DDAH1SLC1A2SLC1A1SLC1A3GRIK1 | |
| SCHEMBL1072051 | 0.83 | GSR (0.45) | DDAH1SLC1A2SLC1A1SLC1A3GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435071-B2 | Bryostatin compounds and methods of preparing the same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-10-07 | — | — | US | disclosed |
| WO-2024083220-A1 | LIGAND-OLIGONUCLEOTIDE CONJUGATE AND LINKER FOR CONJUGATE | 上海京新生物医药有限公司 | 2024-04-25 | — | — | WO | disclosed |
| US-20240116908-A1 | BRYOSTATIN COMPOUNDS AND METHODS OF PREPARING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-04-11 | — | — | US | disclosed |
| US-11746105-B2 | Bryostatin compounds and methods of preparing the same | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-09-05 | — | — | US | disclosed |
| CN-112840031-B | High throughput cloning and use of paired bipartite immunoreceptor polynucleotides | 根路径基因组学公司 | 2023-03-24 | — | — | CN | disclosed |
| CN-109069378-B | Perfume mixture containing ester and ketone | 西姆莱斯股份公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-114828655-A | Docosadiene-1-ols and dodecen-1-ols or mixtures thereof as fragrance chemicals | 巴斯夫欧洲公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-112638419-B | Modified CTLA4 and methods of use thereof | 北京伟德杰生物科技有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-114425045-A | Nano-carrier acting on plasmodium in erythrocytic stage, preparation and preparation method thereof | 山西医科大学 | 2022-05-03 | — | — | CN | disclosed |
| CN-114366746-A | Treatment of cancer using oxoisoindole compounds | 细胞基因公司 | 2022-04-19 | — | — | CN | disclosed |
| US-20050245657-A1 | Compositions for use in golf balls | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2005-11-03 | — | — | US | disclosed |
| US-20050245652-A1 | Compositions for use in golf balls | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2005-11-03 | — | — | US | disclosed |
| US-6489537-B1 | ISOLATED NUCLEIC ACID ENCODING A PHYTOCHELATIN SYNTHASE; TRANSGENIC PLANTS WITH HEAVY METAL RESISTANCE; GROUNDWATER PURIFICATION OF HEAVY METALS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2002-12-03 | — | — | US | disclosed |
| EP-0963219-A4 | MANIPULATIONS OF NITROSATIVE AND OXIDATIVES STRESS IN THE TREATMENT OF DISEASE | UNIV DUKE (US) | 2002-11-13 | — | — | EP | disclosed |
| EP-1179055-A1 | NOVEL PHYTOCHELATIN SYNTHASES AND USES THEREFOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2002-02-13 | — | — | EP | disclosed |
| US-6335317-B1 | ADMINISTERING FIBROBLAST GROWTH FACTOR TO REDUCE GASTROINTESTINAL TRACT OXIDATIVE DAMAGE FROM MALNUTRITION, FASTING, TOXICITY, CHEMOTHERAPY, ALCOHOLISM, IRRADIATION THERAPY | EMORY UNIVERSITY | 2002-01-01 | — | — | US | disclosed |
| US-6228839-B1 | ADMINISTERING BY INJECTION TO PREVENT DAMAGE TO GASTROINTESTINAL TRACT AFTER MALNUTRITION OR CHEMOTHERAPY | EMORY UNIVERSITY | 2001-05-08 | — | — | US | disclosed |
| WO-2000071695-A1 | NOVEL PHYTOCHELATIN SYNTHASES AND USES THEREFOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-0963219-A1 | MANIPULATIONS OF NITROSATIVE AND OXIDATIVES STRESS IN THE TREATMENT OF DISEASE | DUKE UNIVERSITY (US) | 1999-12-15 | — | — | EP | disclosed |
| WO-1998008566-A1 | MANIPULATIONS OF NITROSATIVE AND OXIDATIVES STRESS IN THE TREATMENT OF DISEASE | DUKE UNIVERSITY (US) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746105-B2 | Bryostatin compounds and methods of preparing the same | PROKR1, PBK, PROKR2 | DDAH1 4793/4885SLC1A2 4858/4885SLC1A1 4850/4885 |
| US-20240116908-A1 | BRYOSTATIN COMPOUNDS AND METHODS OF PREPARING THE SAME | PROKR1, PBK, PROKR2 | DDAH1 4793/4885SLC1A2 4858/4885SLC1A1 4850/4885 |
| US-12435071-B2 | Bryostatin compounds and methods of preparing the same | PROKR1, PBK, PROKR2 | DDAH1 4793/4885SLC1A2 4858/4885SLC1A1 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.